Guardant Health shares surged +11.0% in mid-day trading after the U.S. Food and Drug Administration granted approval for the company’s Guardant360 Liquid CDx, a next-generation blood-based cancer testing panel that expands the firm’s core liquid biopsy platform.
The newly approved assay integrates genomic and epigenomic signals to detect circulating tumor DNA and can deliver results in as little as seven days. Company statements and regulatory details note the test provides several-fold improved sensitivity for circulating tumor DNA detection versus the prior version. Importantly, the test evaluates a genomic footprint that is 100 times wider than the previously approved Guardant360 CDx and is authorized as a companion diagnostic for multiple therapies in non-small cell lung cancer and colorectal cancer indications.
The FDA action arrived after a period of strong operational performance at Guardant Health. In the first quarter of 2026, the company reported revenue of $301.7 million, representing a 48.3% year-over-year increase and surpassing Wall Street estimates. Guardant also raised its full-year revenue guidance to $1.31 billion at the midpoint, a figure roughly 3.1% above prior analyst consensus.
Investor sentiment heading into the regulatory approval was bolstered by recent analyst moves. Several major brokerage firms had recently reiterated or upgraded their views on Guardant, with Morgan Stanley and Wells Fargo issuing Buy ratings, while Piper Sandler lifted its price target to $135 in the weeks following the Q1 results.
Market conditions provided an additional tailwind on the day of the announcement. The S&P 500 gained +0.9%, the Dow Jones Industrials rose +1.0%, and the NASDAQ climbed +1.3%, producing a risk-on environment that tends to favor high-growth healthcare and diagnostics names. Peer firms in the liquid biopsy and precision oncology arena, including Natera and GRAIL, operate in the same regulatory and reimbursement landscape; Guardant’s expanded FDA-approved indication strengthens its competitive position and could pressure peers to accelerate development programs.
Share-price action reflected the confluence of regulatory, operational, and analyst factors. Guardant Health stock traded as high as $108.97, above the prior close of $98.19 and nearing the day’s upper range. The recent rally is part of a larger recovery from the company’s 52-week low of $36.36. Management has projected continued revenue growth and is targeting company-wide cash flow breakeven by the end of 2027, and today’s regulatory milestone reinforces the commercial and clinical narrative supporting that outlook.
While the FDA approval marks a significant commercial and clinical advance for Guardant’s flagship platform, the company remains subject to execution risks as it scales utilization of the new test and navigates the broader regulatory and reimbursement environment shared by competitors. For now, the combination of a transformative approval, faster revenue growth, and a supportive analyst base has driven a notable lift in the stock.
Clear summary
The FDA approved Guardant360 Liquid CDx, an expanded liquid biopsy that integrates genomic and epigenomic data, returns results in as little as seven days, and offers several-fold improved sensitivity over the prior version; Guardant Health stock rose +11.0% mid-day amid solid Q1 revenue growth, raised guidance, and favorable analyst coverage, all occurring alongside gains in major U.S. equity indices.